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Abstract
Type 1 Diabetes (T1D), a T cell-mediated autoimmune disease that attacks the pancreas' insulinproducing -cells, has no effective immunotherapy to reverse its progression. Yerba mate (YM)
or Ilex paraguariensis is a natural and inexpensive herbal supplement that has been shown to
have anti-inflammatory properties beneficial in pathogeneses of several diseases. This is the first
study to show YM's potential to delay the onset of T1D. YM’s effects on the progression of the
disease, particularly on T cell populations, was evaluated in two mouse models of T1D using 4%
and 2% w/v infusions ad libitum: streptozotocin (STZ)-induced C57BL/6 (STZ-B6) strain started
YM treatment prior to STZ diabetes induction and continued for 6 weeks, and non-obesediabetic/ShiLtj (NOD) strain started at 5 weeks of age then continued 19 weeks. At the
endpoints, immunological parameters were analyzed from murine splenocytes. YM treatment
decreased glycemia and T1D incidence in the STZ-B6 model. At 4%, but not 2% w/v, YM
significantly decreased glycemia in NOD mice during 19 weeks of treatment without affecting
T1D onset and inducing significant body weight loss. Ex vivo data showed YM treatment in
STZ-B6 mice at both concentrations significantly lowered T cell proliferation, caused transient
changes in T cell immunophenotypes, and suppressed both pro-inflammatory and antiinflammatory cytokine production. In NOD mice, 4% YM w/v caused a transient effect at the 12
weeks of age timepoint, lowering T cell, Th, and Tc populations and reducing production of proinflammatory cytokines IL-6 and IFN-. YM exposure of T cells in vitro caused a dosedependent decrease of T cell proliferation and a dose-dependent reduction and increase of IFN-
and IL-2 production, respectively. Our results corroborate with other studies that tout YM's antiproliferative and hypoglycemic action in addition to its immunomodulatory action on T cells, all
of which suggest a possible therapeutic role of YM in T1D.
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Chapter 1: Introduction
Type 1 Diabetes (T1D) is an autoimmune disease in which the T cells mediate an attack
of the insulin-producing -cells of the pancreas. As insulin stimulates cells to uptake blood
glucose, the halt in producing this hormone leads to high blood sugar (hyperglycemia) and poses
severe complications and even death if not treated. T1D affects children, teens, and young adults
primarily, but it can develop at any age (Rogers et al., 2017). Globally, there are 1.1 million
children and adolescents under 20 with T1D (International Diabetes Federation, 2019). In the
United States, 1.6 million people are suffering from this disease and, with a recent increase in
incidence, prevalence is expected to reach 5 million people by 2050 (Imperatore et al., 2012).
Symptoms are treated with exogenous insulin injections for the patient's lifetime; however, there
is no cure. These injections create a monetary burden that many people try to lighten by rationing
despite consequences to their health (Furst, 2020). Even with treatment, there is a high burden of
complications for adults with young-onset diabetes, including heart and blood vessel disease and
nerve and kidney damage (Fang et al., 2020). A recent study justified the costs of exploring new
treatments for T1D by estimating an $813 billion difference in lifetime healthcare costs of
patients with and without T1D in the United States based on data from more than 1 million
patients (Sussman et al., 2020).
T1D develops from a combination of environmental influences and genetic
predisposition. Presently, non-invasive, traditional herbal remedies with anti-inflammatory or
anti-toxicant properties are being tested to see if they could curtail the onset of the disease.
Yerba mate (YM), or Ilex paraguariensis, is one such herb that is touted to have antiinflammatory properties (Mateos et al., 2017). Its high polyphenol content and observed effects
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on lymphocyte production of tolerogenic cytokines make it a possible supplement to delay the
onset or reduce the severity of T1D.
Pathophysiology of T1D
T1D causes a progressive loss in the function of the -cells in the pancreatic islets of
Langerhans mediated by autoreactive T lymphocytes. Normally, the immune system provides
several checkpoints at which autoreactive cells are terminated. In the case of T1D, one or several
of these checkpoints fail and permit islet-reactive T helper (Th) cells and cytotoxic T (Tc) cells to
launch a delayed-type hypersensitivity reaction. When autoreactive Th cells are presented islet
antigen by dendritic cells in the pancreatic lymph node, they develop into T helper (Th), T
follicular helper (Tfh), peripheral T regulatory (pTreg), or anergic cells (Burrack et al., 2017).
Th cells migrate to the pancreas and release pro-inflammatory cytokines, such as
interferon-gamma (IFN-), interleukin (IL)-17, and tumor necrosis factor-alpha (TNF-), which
induce islet destruction by drawing Tc cells to attack -cells with perforin and granzyme B.
These inflammatory cytokines also cause M1 macrophages to generate reactive oxygen species
(ROS), TNF-, and IL-1b that amplify the -cell death cycle (Burrack et al., 2017).
Concurrently, Tfh cells interact with B cells to produce autoantibodies to the islet antigens,
intensifying the immune response, and pTreg cells dampen the response by generating
transforming growth factor-beta (TGF-b) and IL-10 (Burrack et al., 2017). As T1D progresses,
the autoreactive T cells and autoantibodies increase and overpower any suppressive power of the
Treg cells. Tc cells are the most prevalent cells during this inflammatory infiltration of the islets,
known as insulitis, but macrophages, Th cells, B lymphocytes, and plasma cells are present as
well (Willcox et al., 2009).
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Although Th1 cells are the primary mediators of T1D, other T helper cells exist to induce
inflammation or suppression. T helper 17 (Th17) cells participate in autoimmunity or
inflammation by producing mainly pro-inflammatory IL-17 (Punt et al., 375). T helper 2 (Th2)
cells can suppress inflammation by producing IL-4, which can inhibit naïve T cell differentiation
to Th1 and inhibit Th1 functions (Punt et al., 373-375). Tfh cells do not cause an inflammatory
response but produce cytokines IL-4 and IL-21 to assist in the maturation of B cells (Punt et al.,
377-380).
Hybrid insulin peptides formed between insulin and other pancreatic -cell-derived
peptides, such as proinsulin, glutamic acid decarboxylase, islet antigen-2, and zinc transporter 8,
have been identified as the most credible autoantigens that autoreactive T cells recognize and
attack (Wiles & Delong, 2019). When Tfh cells interact with B cells, autoantibodies form that are
reactive to the aforementioned autoantigens. This formation causes a chronic, subclinical process
of -cell decay that eventually presents itself symptomatically with the clear diagnostic markers
of T1D: hyperglycemia, polydipsia (intense thirst despite drinking fluids), polyphagia (excessive
eating from excess hunger), and polyuria (passing excessive amounts of urine) (American
Diabetes Association, 2018). Genetically, T1D sufferers do not have a singular identifying
marker for disease susceptibility; however, particular human leukocyte antigen (HLA) regions
have a strong correlation with the disease (Erlich et al., 2008) and many loci associated with T1D
correspond to immune responses (Concannon et al., 2009). It is purported that a genetic
predisposition is combined with an environmental influence to initiate the disease. Diet and
vitamin D, including its physiological pathway components, are receiving much focus, as are
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models, such as the hygiene hypothesis and gut microbiome, to explain the environmental role in
the generation of the disease (Atkinson et al., 2014).
Clinically, there are four distinct stages of T1D development, three of which are presymptomatic and have recently been identified in a consensus paper by the Juvenile Diabetes
Research Foundation (JDRF) and the American Diabetes Association: Pre-stage 1, Stage 1, Stage
2, and Stage 3 (Insel et al., 2015). Pre-stage 1 describes the level at which the patient is
genetically susceptible, but no indications of autoimmunity yet exist. Although this stage could
be instrumental for preventative therapy since the supposedly irreversible autoreactive T cell
repertoire has not expanded, “immunotherapy at this stage should be superiorly safe, convenient,
and efficacious in delaying clinical diagnosis” since the degree of risk of getting T1D despite
genetic susceptibility is low with only 20-25% of first-degree relatives developing T1D
(Coppieters & von Herrath, 2018, p.2). During Stage 1, patients remain pre-symptomatic
(maintaining normoglycemia) but begin exhibiting autoimmunity by the presence of
autoantibodies. The forecast of lifetime risk of the disease rises to 100%, and the hope of using
conventional antigenic tolerization strategies dissipate as T cells are fully activated and have
formed a strong memory lineage (Coppieters & von Herrath, 2018). Autoimmunity and presymptomatic characteristics continue in Stage 2, but glucose intolerance (dysglycemia) begins
due to the loss of functional -cell mass (Insel et al., 2015). Distinguishing Stages 1 and 2 is
difficult as the progression is long and varied among individuals (Coppieters & von Herrath,
2018).
Once the patient becomes symptomatic, he or she has reached Stage 3. The autoreactive T
cell repertoire is fully active, and the destruction of the pancreatic islets is advanced, with up to
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90% of their functional -cell mass destroyed. Immunotherapies are not sufficient to restore
normoglycemia at this stage but could permit the survival of any functioning -cells (Coppieters
& von Herrath, 2018). Patients at this stage begin a lifelong dependence on exogenous insulin for
survival. Current immunotherapies include the following: antigen-independent or dependent
strategies, -cell therapies such as islet transplantation, stem cell strategies, and potential novel
strategies including chimeric antigen receptor (CAR) T cells, microbiota modulation, and Janus
kinase (JAK) pathway inhibition (Cabello-Olmo et al., 2019). Antigen-independent strategies
include drugs for immunosuppression, antibody-based therapies to deplete polyclonal B or T
cells, cytokine-based techniques, and therapies that increase tolerogenic dendritic cells and Treg
cells. Antigen-dependent strategies include beta cell-derived autoantigen-based vaccines, insulinreactive -cell depletion, and tolerization of effector T cells (Cabello-Olmo et al., 2019).
Combining these immunotherapies is suggested to be most effective, but there has been no
successful reversal of T1D in humans (Cabello-Olmo et al., 2019).
As the stages of T1D are refined and the screening of individuals improves with
diagnostic technology advancement, the focus of immunotherapy development is turning to PreStage 1. This stage is the “more applicable one … based on the available body of animal model
data” because it is hypothesized that combination therapy of an immunologic agent with a
component to preserve -cell health and function will derive the most significant benefit to the
patient (Coppieters & von Herrath, 2018, p. 5-6).
Mouse Models
One of the most studied animal models for T1D is the non-obese diabetic (NOD) mouse
or NOD/ShiLtJ named by Jackson Laboratories. This model, characterized by spontaneous
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insulitis development by leukocyte infiltrates in females at about 4 weeks of age, ultimately
progresses to fully developed T1D at 12 to 24 weeks or later with a 90-100% incidence in
females, depending on the colony (Leiter, 1997). Inadvertently created in the 1970s in Japan, this
model has been beneficial in understanding the etiology of the disease, especially in those who
are genetically predisposed (Burrack et al., 2017). Etiopathological differences between mice and
humans have caused translational problems in the past, but these models are still valuable tools
when used appropriately. Some limitations of the NOD mouse model are as follows: the NOD
mouse has a gender bias (female mice have a higher incidence rate than male mice whereas T1D
equally affects male and female human subjects), lacks environmental exposure considerations,
and does not imitate the diversity of immunological variation found in humans (Atkinson, 2011).
However, the NOD mice are similar to humans in expressing genes related to the susceptibility
of the disease, developing autoantibodies as the disease develops, and exhibiting insulitis
(Atkinson, 2011). When considering experimental design with mice, Coppieters and von Herrath
(2018) stress the importance of correctly identifying the subclinical stage of the mouse to
compare to the human accurately. Atkinson (2011) also suggests that other models besides the
NOD mouse should be considered.
The C57BL/6 (B6) mouse exposed to a sequence of low-dose injections of the antibiotic
streptozotocin (STZ) is another popular model of T1D. The chemical induction of the STZ-B6
model highlights the environmental trigger for the development of the disease. The -cells of the
pancreas are sensitive to glucose uptake through GLUT2 transporters, and STZ is a glucose
analogue consisting of a glucose moiety attached to cytotoxic nitrosourea (Goyal et al., 2016).
Increasing nitrosourea levels in the -cell cause several mechanisms that induce -cell damage or
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death: formation of the alkylating agent diazomethane, increase of NADPH and free oxygen
radicals, and glucose flux (Goyal et al., 2016). STZ is given at a low dose over five days to limit
cytotoxicity to the pancreas and other tissues. This dosage prevents tissue deterioration, and it
also enlists the T cell repertoire seen in the natural advent of the autoimmune disease (Breyer et
al., 2004). Estrogen interferes with the above actions of STZ, and some mouse strains are not
sensitive to this toxin. The B6 strain, however, is sensitive to STZ; therefore, male mice of this
strain are commonly used for this chemical induction of T1D (Thinamany, 2016).
Although there are limitations, in general, mice are still considered excellent models for
human diseases. Many of the genes in mice share functions of the genes in humans, and both
organisms inherit traits and susceptibility to diseases analogously. Mice, conversely, live shorter
lives, are much smaller, and can be maintained economically. Furthermore, their genomes can be
altered to engender specific models to study an array of diseases. More than one hundred years
of research on mice has established a collection of data, e.g., Mouse Genome Database, shared
worldwide (The Jackson Laboratory).
Yerba Mate, Ilex paraguariensis
Pre-Stage 1 offers the most hope for reversing the course of T1D yet has a high risk to
benefit ratio. Therefore, researchers are currently seeking medicinal and native herbs that can
allay the immunological attack of the pancreatic islets because these substances can be easily and
affordably administered but do not create severe adverse effects. Compounds with high
polyphenol content are even gaining attention for use in the treatment of numerous autoimmune
diseases because of their immunomodulatory ability (Ding et al, 2018, Khan et al., 2019). Ilex
paraguariensis, or YM, is one such compound that is gaining popularity. YM originates from the
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subtropics of South America and is in the genus of the holly plant (Heck & de Meijia, 2007).
Bracesco et al. (2011) describe YM as follows:
“a dioecious evergreen tree, which can grow to an elevation of up to 8–15 m. The 8 cm
long olive-green leaves are perennial, alternate, coriaceous, obovate with slightly crenate
dentate margins and obtuse apex, and have a wedge-shaped base. The petioles are up to
15 mm long. The flowering stage occurs during the spring season, producing small,
unisexual flowers which have 4 white petals. In some tropical or subtropical species, the
number of petals may be 5, 6 or 7. These may be clustered in groups of 1–15 flowers that
appear in the axil of the leaves. The fruits are red-colored berries containing 4–5 seeds”
(p. 379).
The leaves and stems of this plant are cultivated and processed for consumption.
Beverages containing YM are prevalent in South American countries and have been for
centuries. The indigenous Guarani people cultivated and consumed YM before Spanish
colonization, but the Jesuits were the first to discover commercial potential and domesticate the
plant. Traditionally, YM is prepared using a gourd called a “maté” filled with the leaves and a
metal straw called a “bombilla” (small pump). The bombilla has small pores on the bottom so
that when hot water is added, the tea-like beverage can be sipped up without any particulates.
Hot water is added in 20-40mL increments. Then, the liquid is ingested through the bombilla.
Drinking YM is often a social custom where the “maté" is shared among a group of people. A
cold-water version called “tereré” is popular in Paraguay, and a roasted version that is more
similar to common tea called “cha matte” is popular in parts of Brazil (Bracesco et al., 2011).
Interestingly, there is a movement to return to the traditional and indigenous farming of YM to
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create sustainable production of the plant to benefit local ecosystems and economies (Eibl et al.,
2017). Traditional medicine claims YM can reduce cholesterol, obesity, and hypertension and
have anti-inflammatory effects that can reduce diseases such as rheumatism and arthritis
(Habtemariam, 2019).
Yerba Mate Chemistry
YM contains high levels of polyphenols and methylxanthines, both of which have been
shown to have health benefits, including neuroprotection, hypoglycemic action, and antiinflammation (Rio et al., 2013). Mateos et al. (2017) characterized the bioactive compounds of
YM using liquid chromatography/multiple-stage mass spectrometry (LC-MSn) and ferric
reducing ability of plasma (FRAP) assay. They attributed the high antioxidant capacity to the
polyphenolic composition, which was comprised mainly of hydroxycinnamic acid derivatives
(90%) and partly of flavanols (10%) (2017) (Figure 1) (Mateos et al., 2017). The moderate
methylxanthine content, composed mainly of caffeine (90%), did not show a high correlation of
antioxidant activity (Mateos et al., 2017). Compared to other foods with antioxidant properties
such as cocoa, orange juice, and wine, YM showed higher antioxidant activity. According to a
study on the absorption and metabolism of YM in humans by Gómez-Juaristi et al. (2018), the
polyphenols of YM become somewhat bioavailable after being extensively metabolized by
colonic microbiota. After digestion of YM, dihydrocaffeic acids and dihydroferulic acids, which
are conjugated hydroxycinnamic acids, are the most abundant polyphenols in the plasma
(Gómez-Juaristi, 2015). YM’s composition yields favorable outcomes such as antioxidant and
anti-inflammatory properties, adipogenesis regulation (Pang et al., 2008), hypocholesterolemic
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effects (Bravo et al., 2014), weight reduction, and anti-obesity properties (Arçari et al., 2009),
and lessening of atherosclerosis risk factors (Gao et al., 2013).
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Figure 1
Chemical structures of active compounds in YM

Note. a=methylxanthines, b=hydroxycinnamic acid derivatives (Mateos et al., 2018).
Yerba Mate Studies
Many studies focus on the potential of YM to treat Type 2 Diabetes; however, some of
these have found anti-inflammatory effects of YM that could translate to T1D. For example,
Carmo et al. (2012) studied bone marrow cells from high-fat diet (HFD)-induced diabetic rats
and found that the consumption of YM reduced their production of pro-inflammatory cytokines,
IL-1a, IL-6, and TNF-. Similarly, Arçari et al. (2011) evaluated the effects of YM on markers of
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insulin resistance and inflammation of HFD-induced diabetic mice by analyzing serum levels
and liver tissue and found that YM treatment reversed elevated expression of genes for TNF-,
IL-6, and iNOS via the NF-B pathway while reducing blood glucose levels. Similarly,
Puangpraphant et al. (2011) demonstrated that YM inhibits nuclear translocation of NF-B in
macrophages and reduces their inflammatory action.
Recently, Lima et al. (2018) studied the effects of YM extracts in a T1D mouse model
induced with a single high dose of STZ. In this study, YM reduced blood glucose, peripheral
neuropathy, and oxidative damage (Lima, 2018). Although the data support the antiinflammatory effects of YM, the study’s use of a single high dose of STZ is known to induce
strong cytotoxic action that destroyed the b cells of the pancreas without enacting an
autoimmune response characteristic of T1D.
During an in vitro study using human cell lines, Muñoz-Culla et al. (2016) observed that
YM treatment produced a dose-dependent reduction in peripheral blood leukocyte activation of T
cells when they were stimulated with a mitogen. In other in vitro experiments, YM inhibited
topoisomerases in oral carcinoma cells, thereby inhibiting proliferation (Gonzalez de Mejia et al.,
2005). In addition, YM and its phenolic components and metabolites reduced viability and
proliferation of four human cancer cell lines (Amigo-Benavent et al., 2017), protected HepG2
cells induced to have oxidative stress (Baeza et al., 2016), and prevented TNF--induced
oxidative stress in human endothelial cells (Wang et al., 2019). In the case of T1D, suppressing
proliferation of the attacking T cells or reducing oxidative damage incurred by inflammation may
delay or extinguish the development of insulitis and, therefore, the disease.
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Chapter 2: Objectives and Hypothesis
As T1D progresses sub-clinically, a safe supplement to delay the onset of the disease
would be advantageous for those who are genetically susceptible. Pre-Stage 1 has the highest
opportunity for treatment as autoantibodies are not yet present. Still, this stage also has a high
risk-to-benefit ratio when considering treatment options as there is high uncertainty if a person
will develop T1D. Therefore, any supplement that will hinder the body’s attack of the pancreas
must not inflict severe side effects especially considering the disease often begins in childhood.
Even if prevention of T1D is not achievable at this point, any delay of onset would also delay
later complications and improve the patient’s lifelong health. Given the current research
validating its anti-inflammatory properties, YM is a potentially safe and affordable supplement to
delay T1D. Testing the effects of YM on T1D murine models provides necessary information
before YM’s use as a potential supplement for the at-risk human population.
This study determined if YM delays or prevents T1D by altering T cell action. Both T1D
murine models were treated with YM daily and were monitored for changes in glycemic levels
and body weight. Then, immune cells were analyzed ex vivo at the endpoint and at earlier time
points to determine any mechanistic changes otherwise undetectable by glycemic levels alone.
Principally, this study focused on the T cell subsets and their function to see if YM affected their
potential to initiate and propagate a chronic autoimmune inflammatory process. The hypotheses
were as follows:
H0: YM treatment will not affect the development of T1D and glycemic levels in the
STZ-B6 or NOD mouse models nor alter T cell composition and function.
H1: YM treatment will affect the development of T1D in the STZ-B6 and/or NOD mouse
models by delaying the onset of the disease, decreasing glycemia, and altering T cell
composition and function.
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Chapter 3: Materials and Methods
Mice
The B6 and NOD mouse strains were purchased from the Jackson Laboratory (Bar
Harbor, ME, USA) for continued breeding in the Saint Cloud State University (SCSU) Vivarium
with care to maintain best colony management practices. A pilot study for determining the
optimal daily dose of YM for mice consumption was approved by the Institutional Animal Care
and Use Committee (IACUC) of SCSU (Protocol “Pilot Experiment for Determining Fluid
Intake in Mice Orally Exposed to Yerba Mate”; No. 5-125). All other procedures to be performed
on the mice were proposed and approved by SCSU IACUC (Protocol “Effects of Yerba Mate on
the development and severity of Type 1 Diabetes in NOD and streptozotocin-induced mouse
models”, No. 5-127). Mice were housed in BPA-free NexGen Lo-Profile cages in a temperatureand humidity-controlled room with a 12-hour light/dark cycle. They received water and caseinbased phytoestrogen-free diet ad libitum (AIN-93G Rodent Diets, Research Diet, Inc., Harlan
research laboratories). The mice were sexed at sexual maturity and lodged in separate sexed
cages until chosen for experiments; B6 mice were chosen at seven to nine weeks of age, and
NOD mice were chosen at five weeks of age. YM treatment began earlier for NOD mice because
five weeks of age in the NOD model is considered the comparative timepoint to the Pre-stage 1
in humans (Coppieters & von Herrath, 2018). The B6 strain does not have a designated timepoint
that equates to the Pre-stage 1 in humans. Instead, seven- to nine-week-old B6 mice were treated
with YM a week prior to STZ injections to start the YM treatment before the induction of
autoimmunity to simulate the treatment of mice in a “pre-diabetes” phase. Mice assigned to
treatment and control were randomized from their respective litters. Animal care staff observed
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mice daily and reported any health-related issues. At experimental time points and when any
unfavorable health issues arose, mice were euthanized by carbon dioxide asphyxiation, as
described in our IACUC-approved protocol.
Experimental Design: STZ-B6 Mouse Model
B6 mice were separated into three groups and received either ad libitum water, 2% YM
w/v, or 4% YM w/v. YM treatment began at eight to nine weeks of age on what was considered
“day -7” before STZ injections to mimic treatment before an environmental stimulus for the
disease occurs. Low-dose STZ injections were given days 0-4, and bi-weekly body weight and
blood glucose measurements were taken after the injections until the endpoint at day 35 post first
STZ injection. At the endpoint, the mice were euthanized, their spleens removed, and cellular
parameters tested: total splenic cell counts, cell viability, T cell proliferation, major immune cell
phenotypes (B cells, T cells, and macrophages), T cell subsets (Th, Tc, and Treg), and T cell
cytokine concentrations (Figure 2). STZ-B6 mice were followed to day 35 as 70-100% of them
are expected to become diabetic at this time when injected with low-dose STZ. Blood glucose
and body weight measurements were taken bi-weekly to record a quick progression of
hyperglycemia. Mice from the group treated with 4% YM w/v were also euthanized at an early
time point at twelve days post first STZ injection before diabetic state interference.
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Figure 2
Experimental Timeline for STZ-B6 Mouse Model

Experimental Design: NOD Mouse Model
NOD mice were separated into three groups and received either ad libitum water, 2% YM
w/v, or 4% YM w/v. The groups were followed to 24 weeks of age to monitor the incidence of
T1D as 80-90% of female NOD mice exhibit hyperglycemia at this time. At the end of 24 weeks,
mice were euthanized, their spleens removed, and cellular parameters were tested: total cell
counts, cell viability, T cell proliferation, major immune cell phenotypes (B cells, T cells,
macrophages, and NK cells), T cell subsets (Th, Tc, and Treg), and T cell cytokine
concentrations. Additionally, mice from each YM treatment group were euthanized at two early
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time points during T1D development, 12 and 17 weeks of age, to identify YM-induced cellular
changes without diabetic state interference by completing the same assessments mentioned
above. Specifically, the early time points identified differences in the cell populations and their
respective activity as T1D progresses (Figure 3).
Figure 3
Experimental Timeline for NOD Mouse Model

YM Preparation
YM of Uruguayan style was purchased through Amazon (Canarias Yerba Mate Sabor
Tradicional, Brazil). YM infusions of 2% and 4% w/v (4g YM per 100 mL of autoclaved DI
water) were prepared daily and were given to treatment groups ad libitum. A pilot experiment
(SCSU IACUC Protocol No. # 5-125) was conducted following protocols set by Boston
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University to determine the highest concentration at which the mice continued to thrive (Boston
University, 2018). This data revealed that the 4% YM w/v infusion was the highest concentration
to be safely administered orally. While some studies administered YM via gavage, YM was
administered ad libitum orally to reduce the stress on the animal subjects and simulate human
usage.
Daily infusions were prepared following the protocol from Silva et al. (2011).
Autoclaved deionized water was heated to 80°C then removed from the heat. The appropriate
amount of YM was added and fully submerged. Then the infusion steeped for 15 minutes. The
solution was then filtered with sterile coffee filters, cooled to room temperature, and given to
mice in autoclaved BPA-free glass bottles with rubber sips.
Low-Dose Streptozotocin Injections of B6 Mice
STZ was prepared in fresh citrate buffer (0.05 M, pH 4.5, trisodium citrate dihydrate with
4C distilled and autoclaved water) and administered intraperitoneally to both B6 control and
YM treatment groups at a dose of 40 mg STZ/kg body weight and volume of 6.52 L buffer/g
body weight daily for five days (Cetkovic-Cvrlje et al., 2017). Daily YM infusions began seven
days prior to the first STZ injection (day -7).
Evaluation of Glycemic Profile
Blood glucose levels were measured in both strains at the time of starting experiments.
Bi-weekly blood glucose measurements were taken in B6 mice for five weeks after the STZ
administration. Measurements were not taken during STZ injections to reduce additional
manipulations with mice and alleviate their stress. Blood glucose measurements in NOD mice
were taken weekly starting at 12 weeks of age, which is the starting point when insulitis
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progresses sufficiently to induce dysglycemia and continued until 24 weeks of age. Body weights
were measured concurrently with blood glucose measurements for both strains.
For the blood glucose measurements, the lateral tail vein of each mouse was punctured
with a 26Gx5/8 needle to produce a single blood drop while the mouse was carefully held in a 50
mL Falcon tube modified with drilled breathing holes. An Accu-check Aviva glucometer (Roche
Diagnostics, Indianapolis, IN, USA) analyzed the blood sample (mg/dL). Immediately after the
reading was complete, pressure was applied to the puncture site to halt bleeding. The mouse was
then gently returned to its cage.
A mouse was considered diabetic after two consecutive readings at or above 250 mg/dL,
the first of which was considered the time of diabetes onset (Cetkovic-Cvrlje, 2017).
Preparation of Splenic Single Cell Suspension
At time endpoints, mice were euthanized by carbon dioxide asphyxiation following the
guidelines set by NIH with time extended to 10 minutes in the chamber (“Guidelines for
Euthanasia,” 2019).
Spleens from the mice were aseptically harvested in a biosafety cabinet and placed in
Petri dishes containing 5 mL phosphate-buffered salt solution (PBS, Sigma-Aldrich). Each
spleen was then crushed with the flat end of a 10cc syringe plunger through a 70 mm nylon mesh
strainer (BD Falcon, USA) atop a 50 ml Falcon tube, disrupting the pulp of the spleen and
releasing the splenocytes. PBS totaling 5 mL was added to pass cells through the mesh. This
mixture was transferred to a 15 mL Falcon tube and was centrifuged for 5 minutes at 200g 4ºC.
Supernatants were discarded, the pellets were resuspended, and 0.85 mL of ACK lysis buffer
(NH4Cl 8.024g/L, KHCO3 1.0g/L, EDTA Na2· 2H2O 0.003722g/L; 18 Lonza Bio Whittaker,
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Walkersville, MD, USA) was added for 1 minute to lyse erythrocytes. Erythrocytes are more
permeable to ammonium chloride; therefore, this lyses erythrocytes before affecting other cells.
After 1 minute, 5 mL of PBS was added, and cells were centrifuged. Cells were washed with
5mL PBS three more times and collected via centrifugation. After the final wash, cells were
resuspended in 5mL PBS, and cell counts were conducted using a 1:20 dilution in Trypan blue
(Lonza BioWhittaker). Live and dead cells were recorded in two opposing quadrants of the
hemocytometer. The calculated total of live cells for each suspension was used to determine
quantities for further procedures.
T Cell Proliferation Assay
Cells from each splenic cell suspension were seeded in triplicate at 4x105 cells per well
(100 mL) in 96-well microplates in complete medium (CM) (RPMI-1640, 1 U penicillin/mL,
100 µg streptomycin/mL and 10% fetal bovine serum v/v (FBS), Sigma-Aldrich), and incubated
for 72 h (37˚C and 5% CO2 v/v). Each mouse sample had a triplicate for control and a triplicate
with added T cell mitogen, Concanavalin A (ConA, Sigma-Aldrich) at 0.3% w/v, to compare T
cells’ response to this inducing agent of T cell mitosis. After incubation, 10 µl of AlamarBlue
(Invitrogen) was added to each well and incubated for 4-6 hours more. Then, optical densities
were measured by an ELISA plate reader (570nm, GeneMate). AlamarBlue is a blue, cellpermeable, and essentially non-fluorescent dye-containing resazurin, which can be reduced by
the metabolic byproducts of the cells and converted into resorufin, which is red. This dye
changes the color of the media surrounding the T cells and allows changes to be determined by
differences in optical densities.
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Immunophenotyping
Two aliquots of 1x106 splenocytes from each splenic single cell suspension were
transferred to labeled polystyrene tubes in 1 mL of FACS buffer (1xPBS, 0.1% w/v NaN3 w/v,
and 1% FCS v/v in PBS). Tubes were centrifuged for 5 minutes at 200 g at 4ºC. After, the
supernatants were decanted, the pellets were resuspended, and appropriate fluorochrome-tagged
monoclonal antibody mixtures were added in a 1:100 ratio to identify different cell populations
by binding to unique clusters of differentiation (CDs) on the surface of the cells (Table 1). Tubes
were vortexed and incubated in the dark for 45 minutes at 4˚C. Then, the contents were washed
and centrifuged three times with FACS buffer at the above-mentioned rate. Cells were then
resuspended in 0.5 mL FACS buffer, acquired using FACSCalibur (BD Biosciences) flow
cytometer or Accuri C6 Plus (BD Biosciences) flow cytometer, and analyzed using the Cell
Quest Prosoftware (BD Biosciences) or Accuri C6 Plus software (BD Biosciences).

33
Table 1
Cells identified during flow cytometry with unique CD marker and appropriate fluorochromeconjugated monoclonal antibodies (BD Biosciences)
Cell
CD
Antibody-Fluorochrome
All T cells
CD3
Anti-CD3 PE (clone 145-2C11)
T helper (Th1)
CD4
Anti-CD4 PerCP (clone RM4-5)
T cytotoxic (Tc)
CD8
Anti-CD8 FITC (clone 53-6.7)
T regulatory (Treg)
CD4/CD25
Anti-CD25 APC (clone 3C7)
B cells
CD45R/B220
Anti-B220 APC (clone RA3-6B2)
Macrophages
CD11b
Anti-CD11b PerCP (clone M1/70)
Natural Killer Cells (NK)
CD335
Anti-CD335 FITC (clone 29A1.4)
Note. FITC-fluorescein isothiocyanate, PE-phycoerythrin, PerCP-peridinin chlorophyll, and
APC-allophycocyanin
Cytokine Quantification
Splenocytes from each suspension were seeded in two wells, non-stimulated (CM only)
and stimulated (CM + 0.3% ConA), at 4x106 cells per well (1,000 mL) in 24-well microplates
and incubated for 48 h (37˚C and 5% CO2). After incubation, microplates were centrifuged (10
min, 200 g 4˚C), and supernatants were collected. Cytokine quantification was completed using
the CBA Mouse Th1/Th2/Th17 cytokine kit (BD Biosciences, San Jose, California, USA) to
detect IL-2, IL-4, IL-6, IL-10, IL-17, IFN-, and TNF- according to manufacturer’s
instructions. The calibration curves were drawn using a set of diluted cytokine standards (1:2 to
1:256) to determine protein concentrations. Capture beads to identify each cytokine and PE
detection reagent were added to each 50 L of each supernatant and incubated for 2 h in the dark
(20˚C). Samples were acquired with Accuri C6 Plus flow cytometer and analyzed by FCAP v.3.0
array software (BD Biosciences).
In Vitro T Cell Proliferation Study
Splenic single-cell suspensions were made from 8-week-old NOD male mice to
determine the direct interaction of YM with T lymphocytes. Cells were then plated 4x105 per
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100mL for T cell proliferation in triplicate, as described above: non-stimulated (CM) and
stimulated (CM + 0.3% ConA) with each of the following YM concentrations: 0, 0.5, 1, 2, 3.9,
7.8, 15.6, 31.3, 62.5 125, 250, 500, and 1000 g/mL. Additionally, cells were plated in the same
way as described previously, 4x106 per 1000mL for each of the above concentrations of YM for
cytokine determination. Plates were incubated, and proliferation and cytokine analyses were
completed as previously described.
Statistical Analysis
All data were expressed as mean ± SEM. In vivo results were analyzed using JMP Pro 15
statistical software (JMP, SAS, Cary, NC, USA). The results of diabetes incidence were analyzed
using a survival statistical method, and glycemia and body weight measurements were analyzed
using a one-way ANOVA with repeated measures. Cell counts, cell viability, immunophenotypes,
T cell proliferation, and cytokine quantification were analyzed by a two-tailed, unpaired
student’s T-test using Microsoft Excel. For in vivo data of NOD mice treated with YM starting at
7-9 weeks of age, SCSU statistics consultants used SPSS version 27.0 for Windows (SPSS Inc.,
Chicago, Ill., U.S.A.) to analyze the small sample size by a two-tailed, unpaired T-tests. For all
tests, an alpha level of 0.05 was used when determining statistically significant differences
between groups.
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Chapter 4: Results
Determination of YM Dose
A pilot experiment was completed following guidelines for drinking water additives from
Boston University to determine the highest dose of YM at which NOD and B6 mice would thrive
(Boston University, 2018). Originally, YM at a concentration of 7% w/v was chosen as this was
the highest concentration seen in literature for in vivo studies in rodents (Rocha et al., 2018). It
was determined that the consumption of 7% and 5% YM w/v diminished the body weight and
water intake of both strains below the required threshold of 90%. With 4% YM w/v
consumption, however, liquid intake of both strains was maintained. Body weights diminished
slightly but did not fall below 10% of the beginning weight. From this data, 4% w/v was chosen
as the highest dose of YM. All further mention of YM concentration will be weight per volume
unless otherwise stated.
In vivo and ex vivo studies of 4% YM treatment in STZ-induced B6 model of T1D
Diabetes Incidence, Glycemia and Body Weight in STZ-B6 Mice Treated with 4% YM over the
Period of 6 Weeks
After confirming the optimal “high” dose of YM, B6 mice were treated with 4% YM for
a week before receiving low-dose STZ injections over 5 days (day 0-4). Then, body weights and
blood glucose were measured bi-weekly until day 35. Mice treated with 4% YM gradually
increased in weight, similar to the control group (Figure 4a). The average weights of the YM
treatment group were lower (p=.001), but this was caused by the randomized assignment of a
few mice with lower body weight to this group. When weight was analyzed by percent change,
YM-treated mice gained more weight over the 6 weeks than did the control mice (p<.001)
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(Figure 4b). Initially, on day -7, blood glucose measurements for both control and YM treatment
groups were similar (184±6.4 mg/dL and 184±6.7 mg/dL respectively (Mean ± SD), but they
became significantly disparate post-STZ injections (Figure 4c). The values of the control group
reached hyperglycemic levels (≥250 mg/dL) starting day 18 and continued to rise until the
endpoint of 35 days. In contrast, blood glucose levels in the YM treatment group slightly
increased until day 21, when glycemia averaged 210 mg/dL but then declined towards the
endpoint. YM-treated mice had a significantly lower incidence of T1D when compared with
control mice (p<.001) (Figure 4d). In the YM treatment group, the first mouse out of 18
developed overt disease on day 25, whereas 4 of 17 control mice became diabetic on day 11. The
control group reached 50% diabetes incidence on day 18, while the YM treatment group did not
reach the 50% threshold throughout the entire experimental period. The YM-treated mice
maintained 89% diabetes-free by the endpoint, while control mice remained only 29% diabetesfree.
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Figure 4
Body weights (A), percent change of body weights from initial weights (B), blood glucose (C),
and incidence of T1D (D) of STZ-B6 mice treated with 4% YM over the period of 6 weeks

Note. B6 mice were treated with 4% YM from day -7 to day 35 post first STZ injection. Initial
body weights and blood glucose were taken on day -7 and monitored bi-weekly starting day 7
post first STZ injection. Incidence of TID is presented as a percentage of diabetes-free mice.
Onset of the disease was defined by the first of two consecutive glycemia readings  250 mg/dL.
Values are shown as means ± SEM. * p<.05, **p<.001 compared with controls (MANOVA: A-C,
Survival analysis: D). Legend: C=vehicle control; 4%YM=4% (w/v) YM ad libitum
Ex vivo Immunological Studies in STZ-B6 Mice Treated with 4% YM at 35-Day Endpoint
Cell counts from the splenic single-cell suspension were completed at the endpoint, 35
days post initial STZ injection, and viability was analyzed (Figure 5a and 5b). YM-treated mice
did not vary significantly in either category from control mice. When analyzing T cell
proliferation by comparing optical densities of ConA-stimulated splenic cells to non-stimulated
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cells, the YM treatment group had statistically lower optical densities for stimulated cells
(p=.045) (Figure 5c). When proliferation indices were calculated, T cell proliferation of the YM
treatment group with an index of 1.8 ± 0.7 (Mean ± SD) was significantly suppressed compared
to the control group with an index of 6.1 ± 4.1 (p<.001) (Figure 5d).
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Figure 5
Cell counts (A), cell viability (B), normalized optical densities of T cell proliferation (C), and T
cell proliferation indices (D) obtained from the spleens of STZ-B6 mice treated with 4% YM at
the endpoint of the experiment

Note. B6 mice were treated by 4% YM from day -7 to day 35 post first STZ injection when their
spleens were removed and single-cell suspensions made. Cell counts (A) and viability (B) were
determined by Trypan blue exclusion tests using a hemocytometer. T cell proliferation was
induced by ConA during a 72-hour incubation period. Then, AlamarBlue reagent was added, and
optical densities (OD) were determined (C). The proliferation index was calculated by dividing
the OD of ConA-stimulated cells by the OD of non-stimulated cells (D). Values are shown as
means ± SEM, * p<.05, **p<.001 compared with controls using student’s T-test. Legend:
C=Vehicle control; 4%YM=4% (w/v) YM ad libitum
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Despite major differences in glycemic levels and incidence of T1D, immunophenotypes
of cells did not vary significantly between the groups, except Treg cells were significantly lower
in the YM treatment group than the control group (p=0.03) (Figure 6a). All following cytokines
in the YM treatment group were lower than those of the control group with significant decreases
in levels of pro-inflammatory [IL-6 (p=.014), IFN- (p=.042), TNF- (p=.012)] and antiinflammatory [IL-4 (p=.003) and IL-10 (p=.002)] cytokines (Figure 6b). A trend of decreased IL17a production was also evident (p=.088).
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Figure 6
Immunophenotypes (A) and cytokine concentrations (B) obtained from the spleens of STZ-B6
mice treated with 4% YM at the endpoint of the experiment

Note. Splenocytes from B6 mice treated by 4% YM from day -7 to day 35 post first STZ
injection were stained with fluorochrome-conjugated monoclonal antibodies listed in table 1 and
analyzed by flow cytometry (A). CBA Mouse Th1/Th2/Th17 cytokine kit was used to determine
cytokine concentrations from the supernatants of splenocytes stimulated by ConA during a 48hour incubation period (B). Values are shown as means ± SEM, * p<.05 compared with controls
using student’s T-test. Legend: C=Vehicle control; 4%YM=4% (w/v) YM ad libitum
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Ex vivo Immunological Studies in STZ-B6 Mice Treated with 4% YM at Early Timepoint
To analyze YM’s effects on B6 mice injected with low-dose STZ before the onset of
T1D, mice were sacrificed on day 12 post first STZ injection, 19 days after beginning YM
treatment. At this point, all mice (5/5; 100%) in the YM treatment group maintained normal
glycemic levels, but 3 of 5 mice in the control group had hyperglycemic measurements (³ 250
mg/dL). Therefore, YM-treated mice had significantly lower glycemic levels than the control
mice (p=.019) at that timepoint. No significant differences in total cell counts, cell viability, or T
cell proliferation were found between the YM treatment and control groups (Figures 7a, 7b, 7c,
and 7d). Immunophenotypes varied between the two groups: the YM treatment group had higher
Tc cells (p<.001), lower Treg cells (p=.001), and lower natural killer cells (p=.006) than the
control group (Figure 7e). All cytokines from the YM treatment group did not vary significantly
from the control group (Figure 7f).
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Figure 7
Cell counts (A), cell viability (B), normalized optical densities of T cell proliferation (C), T cell
proliferation indices (D), immunophenotypes (E), and cytokine concentrations (F) obtained from
the spleens of STZ-B6 mice treated with 4% at day 12 post initial STZ injection

Note. B6 mice were treated with 4% YM from day -7 to day 12 post first STZ injection. Refer to
notes from figure 5 (A-D) and figure 6 (E&F). Values are shown as means ± SEM, * p<0.05
compared with controls using student’s T-test. Legend: C=Vehicle control; 4%YM=4% (w/v)
YM ad libitum
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In vivo and ex vivo studies of 2% YM treatment in STZ-induced B6 model of T1D
Diabetes Incidence, Glycemia and Body Weight in STZ-B6 Mice Treated with 2% YM over the
Period of 6 Weeks
The effectiveness of a lower dose of YM was determined by treating STZ-induced B6
mice with 2% YM to the endpoint of 35 days. Weight and percent body weight change did not
differ significantly between YM-treated and control groups (Figures 8a and 8b). Blood glucose
values were significantly lower for YM-treated mice compared to the control mice (p=.046), with
blood glucose averaging 219.9±49 mg/dL (Mean ± SD) for YM treatment and 268.5±145mg/dL
(Mean ± SD) for control at the endpoint (Figure 8c). There was significantly decreased T1D
incidence in YM-treated mice than in the control mice (p=0.046) (Figure 8d). At the endpoint, 3
of 11 mice (27%) in the YM-treated group were diabetic compared to 7 of 11 mice (64%) in the
control group, with more than 50% of control mice becoming diabetic by day 11.
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Figure 8
Body weights (A), percent change of body weights from initial weights (B), blood glucose (C),
and incidence of T1D (D) of STZ-B6 mice treated with 2% YM over the period of 6 weeks

Note. B6 mice were treated with 2% YM from day -7 to day 35 post first STZ injection. Initial
body weights and blood glucose were taken on day -7 and monitored bi-weekly starting day 7
post first STZ injection. Incidence of TID is presented as a percentage of diabetes-free mice.
Onset of disease was defined by the first of two consecutive glycemia readings  250 mg/dL.
Values are shown as means ± SEM. * p<.05 compared with controls (MANOVA: A-C, Survival
analysis: D). Legend: C=Vehicle control; 2%YM=2% (w/v) YM ad libitum
Ex vivo immunological studies in STZ-B6 Mice Treated with 2% YM at 35-Day Endpoint
Ex vivo data were collected at the endpoint. Cell counts were significantly lower in the
YM treatment group compared to the control group (p=.001) (Figure 9a). This difference was
mostly due to human error of lysing cells with ACK lysing buffer longer than the protocol
directed for 5 YM-treated samples. Despite the difference in total number of cells, viability of the
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cells did not vary between YM-treatment and control groups (Figure 9b). Optical densities of
ConA-stimulated splenic cells to non-stimulated cells did not differ between the YM treatment
and control groups (Figure 9c). T cell proliferation indices varied significantly; the YM treatment
group was significantly lower than the control group (p=.013) (Figure 9d). The YM-treated
group expressed elevated T cells (p=.016), Tc cells, and Th cells (p<.001) compared to the
control group (Figure 9e). In addition, the YM-treated group also expressed a reduced B cell
population (p=.006) compared to the control group (Figure 9e). Cytokines trended in the same
direction as those from the 4% YM treatment group: except for IL-2, cytokines from the 2% YM
treatment group were lower than the controls (Figure 9f). However, the 2% YM treatment group
only showed significantly lower IL-4 (p=.03) than the controls.
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Figure 9
Cell counts (A), cell viability (B), normalized optical densities of T cell proliferation (C), T cell
proliferation indices (D), immunophenotypes (E), and cytokine concentrations (F) obtained from
the spleens of STZ-B6 mice treated with 2% YM at the endpoint of the experiment

Note. B6 mice were treated with 2% YM from day -7 to day 35 post first STZ injection. Refer to
notes from figure 5 (A-D) and figure 6 (E&F). Decreased cell counts of 2% YM-treated STZ-B6
mice attributed to human error. Values are shown as means ± SEM, * p<0.05 compared with
controls using student’s T-test. Legend: C=Vehicle control; 2%YM=2% (w/v) YM ad libitum
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In vivo and ex vivo studies of 4% YM treatment in NOD mouse model of T1D
In vivo pilot experiment with 4% YM
NOD mice 7-9 weeks old were treated with 4% YM until 24 weeks of age to confirm that
the mice could withstand treatment for the duration of the experiment. Body weights of YMtreated mice slightly declined around 19 weeks of age compared to control mice (Figure 10a and
10b). Glycemic levels of the YM treatment group rose less than that of the control, with blood
glucose averaging 600±0 mg/dL (Mean ± SD) for control and 317.2±115 mg/dL (Mean ± SD) for
YM treatment at the endpoint (Figure 10c). The onset of T1D for the control group was observed
at 18 weeks of age and for the YM treatment group at 19 weeks of age. By 19 weeks of age, the
control group dropped below 50% diabetes-free, and all the control mice became diabetic by 21
weeks of age, while the YM treatment group maintained 60% diabetes-free until the endpoint
(Figure 10d). During the experiment, 3 control and 2 YM treatment mice became hyperglycemic
with levels above 600 mg/dL and were euthanized before the endpoint.
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Figure 10
Body weights (A), body weights by percent change (B), blood glucose levels (C), and incidence
of T1D (D) of female NOD mice treated with 4% YM from 7-9 weeks of age to 24 weeks of age

Note. Initial body weights and blood glucose were taken the first day of 4% YM treatment and
then monitored weekly from 12 to 24 weeks of age. Incidence of TID is presented as a
percentage of diabetes-free mice. Diabetes onset was defined by the first of two consecutive
glycemia readings  250 mg/dL. Values are shown as means ± SEM. No statistical significance
was evident (MANOVA: A-C, Survival analysis: D). Legend: C=Vehicle control; 4%YM=4%
(w/v) YM ad libitum
Diabetes incidence, glycemia, and body weight in NOD mice treated with 4% YM over the
period of 19 weeks
As the mice treated with 4% YM in the pilot experiment demonstrated lower glycemic
levels and a lower rate of diabetes incidence, a new set of experiments was started to test the
efficacy of YM treatment in younger NOD mice with anticipation that YM could better hinder
the etiopathogenesis of T1D when administered earlier in the development of the disease.
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Therefore, 5-week-old NOD mice began YM treatment since this age is most comparable to the
human pre-stage 1 of T1D.
NOD mice treated with 4% YM from 5 weeks of age to 24 weeks of age significantly
diminished body weight starting around 19 weeks of age compared to controls (p=.046) (Figure
11a). This difference became more pronounced when percent body change was compared
(p=.035) (Figure 11b). Glycemic values were similar for YM treatment and control groups at the
commencement of the experiment (119.5±3.5 mg/dL and 106.6±4.4 mg/dL, respectively)(Figure
11c). Still, YM caused a significant decrease in glycemic values of the treated mice throughout
the entire experimental period compared to the controls (glycemia measured at the endpoint was
433.9±40.3 mg/dL and 479.6±43.9 mg/dL, respectively) (p=.029). Despite the effects of YM on
glycemic levels, the incidence of T1D between the groups did not vary significantly. The onset of
T1D occurred at 12 weeks of age in the control group and 14 weeks of age for the YM treatment
group (Figure 11d). Both groups reached 50% incidence of T1D within a few weeks; 50% of
control and YM-treated mice became diabetic at 18 and 21 weeks of age, respectively. A similar
percent of mice in each group remained diabetes-free at the endpoint: 27% in the control and
26% in the YM treatment group. In half of the YM-treated mice, it was observed that mice,
starting at various time points from 11 to 18 weeks of age, developed dried, scabby tails and
alopecia around the muzzle or crown of the head and upper back, so-called “barbering.”
However, scabby tails were also observed in littermates from the same breeders that did not
participate in this study, so other factors, not YM treatment per se, may have evoked this
condition (Burkholder et al., 2012). Also, one mouse in the control group manifested
neurological issues and was euthanized and excluded from the study.
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Figure 11
Body weights (A), body weights by percent change (B), blood glucose levels (C), and incidence
of T1D (D) of female NOD mice treated with 4% YM from 5 weeks of age to 24 weeks of age

Note. Initial body weights and blood glucose were taken the first day of 4% YM treatment and
then monitored weekly from 12 to 24 weeks of age. Incidence of TID is presented as a
percentage of diabetes-free mice. Diabetes onset was defined by the first of two consecutive
glycemia readings  250 mg/dL. Values are shown as means ± SEM, * p<0.05 compared with
controls (MANOVA: A-C, Survival analysis: D). Legend: C=Vehicle control; 4%YM=4% (w/v)
YM ad libitum
Ex vivo immunological studies in NOD mice treated with 4% YM at 24 weeks of age endpoint
Although 4% YM-administered mice lost weight throughout treatment, no significant
differences were found in the splenic cell counts (Figure 12a), cell viability (Figure 12b), T cell
proliferation (Figure 12c and 12d), or immunophenotypes (Figure 13a) between the YM-treated
mice and the control mice. The YM treatment group, however, produced significantly lower
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concentrations of anti-inflammatory IL-4 (p=.003) and IL-10 (p=.036), and pro-inflammatory IL17 (p=.005) than the control group (Figure 13b). The sample size for the cellular parameters was
smaller than that of incidence because sickly mice who were hyperglycemic above 600 mg/dL
were humanely euthanized before reaching the endpoint at 24 weeks of age. In the control
group, 8 of 22 mice reached 24 weeks of age, 3 of which were diabetic (3/8; 37.5% diabetic mice
at 24 weeks). In the YM treatment group, 12 of 23 mice reached 24 weeks of age, 7 of which
were diabetic (7/12; 58% diabetic mice at 24 weeks).
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Figure 12
Cell counts (A), cell viability (B), normalized optical densities of T cell proliferation (C), and T
cell proliferation indices (D) obtained from the spleens of 24-week-old female NOD mice treated
with 4% YM starting at 5 weeks of age

Note. NOD mice were treated by 4% YM from 5 to 24 weeks of age when their spleens were
removed, and single-cell suspensions were made. Cell counts (A) and viability (B) were
determined by Trypan blue exclusion tests using a hemocytometer. T cell proliferation was
induced by ConA during a 72-hour incubation period. Then, AlamarBlue reagent was added, and
optical densities (OD) were determined (C). The proliferation index was calculated by dividing
the OD of ConA-stimulated cells by the OD of non-stimulated cells (D). Values are shown as
means ± SEM. Legend: C=vehicle control; 4%YM=4% (w/v) YM ad libitum
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Figure 13
Immunophenotypes (A) and cytokine concentration (B) obtained from the spleens of 24-week-old
female NOD mice treated with 4% YM starting at 5 weeks of age

Note. Splenocytes from NOD mice treated by 4% YM from 5 weeks of age to 24 weeks of age
were stained with fluorochrome-conjugated monoclonal antibodies listed in table 1 and analyzed
by flow cytometry (A). Cytokine concentrations were determined from the supernatants of
splenocytes stimulated by ConA during a 48-hour incubation period using CBA Mouse
Th1/Th2/Th17 cytokine kit (B). Values are shown as means ± SEM, * p<.05 compared with
controls using student’s T-test. Legend: C=Vehicle control; 4%YM=4% (w/v) YM ad libitum
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Ex vivo immunological studies in NOD mice treated with 4%YM at 12 weeks of age timepoint
As the data taken at the 24 weeks of age endpoint had a small sample size due to early
euthanasia of diabetic subjects, ex vivo data were collected from mice treated with 4% YM
starting at 5 weeks of age until 12 weeks of age. At 12 weeks of age, most NOD mice are not yet
overtly diabetic, with glycemic values below or near 250 mg/dL. Cellular data, therefore, can be
collected on a larger number of subjects and illuminate the immunological changes occurring
during the subclinical onset of T1D. In contrast, the diabetic state of 24-week-old mice might
have altered immunological parameters that confound the effects of YM treatment.
None of the mice euthanized in YM treatment or control groups was diabetic at the early
time point. Cell counts and cell viability did not vary significantly between the YM-treated and
control groups at this time point (Figure 14a and 14b). Exposure to the T cell mitogen did not
cause significant differences during cell proliferation, as seen in the normalized optical densities
and proliferation indices (Figure 14c and 14d). Unlike the mice from the 24 weeks of age
endpoint, the mice at the early 12 weeks of age timepoint differed significantly in several
immunophenotypes (Figure 14e). The YM treatment group had lower percentages of T cell
(p=.002), T helper (p=.01), and T cytotoxic (p=.004) populations when compared to control. It
also had a higher B cell percentage (p=.001) when compared to the control. The levels of all
tested cytokines, besides IL-2, were lower in the YM treatment group when compared to the
controls; however, IL-6 (p=.035) and IFN- (p=.05) reached statistical significance (Figure 14f).
IL-17a and TNF- had borderline significance (p=.069 and p=.092 respectively).
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Figure 14
Cell counts (A), cell viability (B), normalized optical densities of T cell proliferation (C), T cell
proliferation indices (D) immunophenotypes (E), and cytokine concentrations (F) obtained from
the spleens of 12-week-old female NOD mice treated with 4% YM starting at 5 weeks of age

Note. NOD mice were treated by 4% YM from 5 weeks of age to 12 weeks of age. See notes in
figure 12 for A-D and figure 13 for E-F. Values are shown as means ± SEM, * p<0.05,
**p<0.001 compared with controls (student’s T-test). Legend: C=Vehicle control; 4%YM=4%
(w/v) YM ad libitum
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Glycemia and body weight in NOD mice treated with 4% YM up to 17 weeks of age timepoint
NOD mice treated with 4% YM beginning at 5-6 weeks of age were sacrificed at 17
weeks of age to continue tracking immunological changes during T1D progression. According to
The Jackson Laboratory, the median incidence of T1D in NOD females is 18 weeks of age, so 17
weeks permitted the study of ex vivo data when the onset of T1D was imminent (The Jackson
Laboratory). At this time point, one mouse in the control group had an elevated blood glucose
reading (250mg/dL), and two mice in the YM treatment group were considered diabetic. One
mouse from each group was euthanized before the 17-week time point due to the early onset of
T1D evident by recurrent high blood sugar readings (600 mg/dL). Thus, 2/10 (20%) and 3/10
(30%) were diabetic in the control and YM-treated groups, respectively, by 17 weeks of age.
Body weights of the YM-treated mice were lower than that of the control mice (Figure 15a).
However, the percent change of body weights did not indicate the loss of body weight in the
group administered with YM; rather, the YM treatment group exhibited a trend of greater
increased body weight than that of the control group (Figure 15b). These data were consistent
with the body weight data from the experiment in which mice were long-term-treated up to 24
weeks of age endpoint; in that study, body weight did not begin to decline around 19 weeks of
age (Figures 11a and 11b).
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Figure 15
Body weights (A) and percent change of body weights (B) of female NOD mice treated with 4%
YM from 5 weeks of age to 17 weeks of age

Note. Legend: C=Vehicle control; 4%YM=4% (w/v) YM ad libitum
Ex vivo immunological studies in NOD mice treated with 4% YM at 17 weeks of age timepoint
Cell counts (Figure 16a) and viability (Figure 16b) did not vary significantly between the
groups. Normalized optical densities of the T cell proliferation assay did not differ significantly
between groups, but the proliferation index was significantly higher for the YM treatment group
than the control group (p=.030) (Figures 16c and 16d). For immunophenotypes of cells, most
populations did not vary significantly, but T cells (p=.035) and Treg (p=.002) populations were
significantly lower in the YM treatment group than those of the control group (Figure 16e).
Cytokine profiles differed from those acquired at the 12 weeks of age timepoint. Whereas most
cytokines concentrations at the early timepoint decreased, YM treatment caused an increase in
most cytokines at 17 weeks of age timepoint, with significantly higher TNF- compared to the
control (p=.046) (Figure 16f). IL-6 and IL-10 trended toward higher concentrations in the treated
mice compared to the controls (p=.076 and p=.09, respectively).
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Figure 16
Cell counts (A), cell viability (B), normalized optical densities of T cell proliferation (C), T cell
proliferation indices (D), immunophenotypes (E), and cytokine concentrations (F) obtained from
the spleens of 17-week-old female NOD mice treated with 4% YM starting at 5 weeks of age

Note. NOD mice were treated by 4% YM from 5 to 17 weeks of age. See notes in figure 12 for
A-D and figure 13 for E-F. Values are shown as means ± SEM, * p<0.05 compared to controls
(student’s T-test). Legend: C=Vehicle control; 4%YM=4% (w/v) YM ad libitum
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In vivo and ex vivo studies of 2% YM treatment in NOD mouse model of T1D
Diabetes incidence, glycemia, and body weight in NOD mice treated with 2% YM over the
period of 19 weeks
To determine if a lower dose of YM treatment could effectively prevent TID in the NOD
mouse model, NOD females, 5-6 weeks of age, were treated with 2% YM until 24 weeks of age.
During this time, there was no statistically significant difference in body weights, blood glucose
levels, or incidence of T1D between the YM treatment and control groups (Figures 17a, 17b,
17c, and 17d). YM-treated mice maintained similar body weights as the controls until about 18
weeks of age, after which point their body weights began to decrease, although not significantly.
This pattern was analogous to the change in body weights of the NOD mice treated with 4% YM.
Similarly, blood glucose levels of the YM treatment group were comparable to that of the control
group through 17 weeks of age. After this point, the YM treatment group had a trend of higher
blood glucose levels than the control group (Figure 17c). At 12 weeks of age, both groups had
their first case of overt disease, with one diabetic out of 21 mice (95%) each. The YM treatment
group was 50% diabetic by 18 weeks of age, whereas the control group was 50% diabetic at 20
weeks of age. At the endpoint, 24% of YM-treated mice remained non-diabetic with an average
glycemia of 481±45 mg/dL (Mean±SD) compared to 33% of the control mice that remained nondiabetic with an average glycemia of 450 ± 48 mg/dL (Figure 17d).
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Figure 17
Body weights (A), body weights by percent change (B), blood glucose levels (C), and incidence
of T1D (D) in female NOD mice treated with 2% YM from 5 weeks of age to 24 weeks of age

Note. Initial body weights and blood glucose were taken the first day of 2% YM treatment and
then monitored weekly from 12 to 24 weeks of age. Incidence of TID is presented as a
percentage of diabetes-free mice. Diabetes onset was defined by the first of two consecutive
glycemia readings  250 mg/dL. Values are shown as means ± SEM. No statistical significance
was evident (MANOVA: A-C, Survival analysis: D). Legend: C=Vehicle control; 2%YM=2%
(w/v) YM ad libitum
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Ex vivo immunological studies in NOD mice treated with 2% YM at 24 weeks of age endpoint
Ex vivo data were obtained from the mice that reached the 24 weeks of age endpoint. Ten
control mice reached the endpoint, three of which were considered diabetic (3/10; 30%). Five
YM-treated mice reached the endpoint, one of which was diabetic (1/5; 20%). There were no
statistically significant differences in cell counts, cell viability, T cell proliferation, or
immunophenotypes between the groups (Figures 18a-e). While not significant, the YM treatment
group exhibited a trend in lower T cell, T helper cell, and T cytotoxic cell populations compared
to controls (Figure 18e). The YM treatment group conversely had a trend of a higher percentage
of B cell population compared to the controls. These trends match immunophenotype data from
the 12 and 17 weeks of age NOD mice treated with 4% YM.
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Figure 18
Cell counts (A), cell viability (B), normalized optical densities of T cell proliferation (C), T cell
proliferation indices (D), and immunophenotypes (E) obtained from the spleens of 24-week-old
female NOD mice treated with 2% YM starting at 5 weeks of age

Note. NOD mice were treated by 2% YM from 5 weeks of age to 24 weeks of age. See notes in
figure 12 for A-D and figure 13 for E. Values are shown as means ± SEM, * p<0.05 compared
with controls (student’s T-test). Legend: C=Vehicle control; 2%YM=2% (w/v) YM ad libitum
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Ex vivo immunological studies in NOD mice treated with 2% YM at 12 weeks of age timepoint
While the 2% YM treatment and control groups at the 24 weeks of age endpoint did not
differ significantly in immunological parameters, some significant differences occurred in the
female NOD mice treated with 2% YM at the 12 weeks of age timepoint. Cell counts (Figure
19a) and cell viability (Figure 19b) did not differ between YM treatment groups and control
groups, but proliferation and immunophenotypes did. The YM treatment group had higher nonstimulated and stimulated T cell proliferation levels (p<.001 and p=.011, respectively) (Figure
19c) but a lower proliferation index (p=.014) than that of the controls (Figure 19d). Also, the
YM treatment group had a significantly lower Th cell population than the control group (p=.015)
(Figure 19e).
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Figure 19
Cell counts (A), cell viability (B), normalized optical densities of T cell proliferation (C), T cell
proliferation indices (D), and immunophenotypes (E) obtained from the spleens of 12-week-old
female NOD mice treated with 2% YM starting at 5 weeks of age

Note. NOD mice were treated by 2% YM from 5 weeks of age to 12 weeks of age. See notes in
figure 12 (A-D) and figure 13 (E). Values are shown as means ± SEM, * p<0.05 compared with
controls (student’s T-test). Legend: C=Vehicle control; 2%YM=2% (w/v) YM ad libitum
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Ex vivo immunological studies in NOD mice treated with 2% YM at 17 weeks of age timepoint
Mice treated with 2% YM from 5 to 17 weeks of age did not vary in cell counts (Figure
20a) or cell viability (Figure 20b), but they showed similar trends in T cell proliferation as the
groups analyzed at 12 weeks of age timepoint. The YM treatment group had significantly higher
non-stimulated and stimulated T cell proliferation values (p=.004 and p=.008, respectively) and a
lower proliferation index than the controls (Figure 20c and 20d). At this timepoint, Tc and Treg
cells were significantly lower than controls (p=.027 and p=.001, respectively), with a trend in
lower T and Th cells (Figure 20e).
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Figure 20
Cell counts (A), cell viability (B), normalized optical densities of T cell proliferation (C), T cell
proliferation indices (D), and immunophenotypes (E) obtained from the spleens of 17-week-old
female NOD mice treated with 2% YM starting at 5 weeks of age

Note. NOD mice were treated by 2% YM from 5 weeks of age to 17 weeks of age. See notes in
figure 12 for A-D and figure 13 for E. Values are shown as means ± SEM, * p<0.05 compared
with controls (student’s T-test). Legend: C=Vehicle control; 2%YM=2% (w/v) YM ad libitum

68
YM effects on T cell function in vitro
T cell proliferation assays (n=3) were performed by treating cells obtained from 2-monthold male NOD mice with 0.5-1000 µg/mL of YM in vitro to observe its direct effect on T cells. T
cell proliferation indices from cells treated with 0-1000 µg/mL YM displayed a trend of a dosedependent decrease (Figure 21), with the following concentrations produced significantly lower
T cell proliferation indices when compared to the control: 125 (p=.05), 250 (p=.04), 500
(p=.018), and 1,000 (p=.008) µg/mL YM.
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Figure 21
T cell proliferation induced by ConA with the addition of different concentrations of YM in vitro

Note. T cell proliferation was induced in NOD splenocytes by ConA with or without the addition
of different concentrations of YM (0.5 to 1000 µg/mL) during a 72-hour incubation period.
Optical densities (OD) were determined spectrophotometrically after AlamarBlue addition and
proliferation indices calculated by dividing ODs of ConA-stimulated cells by ODs of nonstimulated cells for each YM concentration. Values are shown as means ± SEM of 3 experiments,
* p<0.05 compared with control (student’s T-Test).
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Cytokine concentrations were analyzed in ConA-stimulated NOD splenocytes treated
with 0.5-1,000 µg/mL YM (n=3). When compared to the secretion of control T cells, treatment
with 1,000 µg/mL YM significantly decreased production of IL-4 (p=.009), IL-6 (p=.014), IFN-
(p=.008), and TNF- (p<.001); and it caused a trend of decreased production of IL-2 (p=.069),
IL-10 (p=.083), and IL-17 (p=.156) (Figure 22a-g). Interestingly, the next highest concentration
of YM, 500 µg/mL, did not affect the levels of TNF-, IL-6, IL-10, and IL-4, while decreasing
IFN- production (p=.03) compared to the control. IFN- was the only cytokine for which a trend
in dose-dependent suppression of secretion was observed. In contrast, IL-2 levels seemed to be
dose-dependently increasing with the addition of YM up to 500 µg/ml; however, statistical
significance was not confirmed except with 250 µg/ml compared to the control (p=.036).
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Figure 22
Cytokine production of ConA stimulated T cells exposed to 0-1000 µg/mL YM in vitro

Note. Splenocytes obtained from NOD mice were stimulated by ConA with or without the
addition of different concentrations of YM (0.5 to 1000 µg/mL) during a 48-hour incubation
period. Supernatants were then collected and analyzed using CBA Mouse Th1/Th2/Th17
cytokine kit. Values are shown as means ± SEM of 3 experiments; * p<0.05 compared to 0
µg/mL YM (student’s T-Test). Legend: A:IL-2, B:IL-4, C:IL-6, D:IFN-, F:TNF-, G:IL-10
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Chapter 5: Discussion
T1D is an autoimmune disease in which autoreactive T cells attack the insulin-producing
-cells of the pancreas. Since many attempts to halt the progression of -cell destruction have
failed, research is now focusing on prevention, particularly in the pre-stage 1 where an entire T
cell repertoire for an attack is not yet established during a delayed-type hypersensitivity reaction.
Current literature purports yerba mate’s high polyphenol content to have anti-inflammatory and
hypoglycemic properties, making it an excellent candidate to delay the progression of T1D
without causing severe side effects an immunotherapeutic drug may inflict. This is crucial
because pre-disposition to T1D during pre-stage 1 does not ensure the eventual onset of the
disease, so any preventative therapies must be exceptionally safe.
Reports have stated that the average person in South America consumes 1-2 L of YM
infusion per day, with the highest consumption occurring in Uruguay with an estimated 6-8 kg
YM/person/year (Bracesco et al., 2011). Gao et al. (2013) estimated that the daily dose of YM
for the average human adult in Argentina is 0.2 g YM/kg body weight. In murine models, the
YM has been commonly administered either by gavage or ad libitum in doses that ranged from 1
mg YM/kg per day (Açari et al., 2011) to 850 mg YM/kg per day (Lima et al., 2018) via gavage,
and from 1%, 2%, and 4% (Gao et al., 2013), 5% (Bravo et al., 2014) to 7% (w/v) (Rocha et al.,
2018) ad libitum YM infusion daily. Our pilot experiment confirmed that 4% is the highest
concentration mice can tolerate YM infusion ad libitum.
Using 4% as the highest concentration of YM, we assessed the efficacy of YM to delay
the onset of T1D by altering T cell population and function using STZ-B6 mice and NOD mice
models. Overall, while YM reduced glycemia in both mouse models, YM treatment affected the
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two differently (Tables 2 and 3). STZ-B6 mice treated with 4% YM increased in weight and
maintained normoglycemia compared to the control. After 6 weeks, 4% YM-treated mice
remained 80% diabetic free whereas the control mice only had 29% diabetic-free mice
remaining. At first, we thought YM could be directly interacting with STZ to prevent the
chemical induction of T1D. However, the YM-treated mice displayed distressed T cell responses,
reduced T cell proliferation as well as reduced inflammatory (IL-6, IFN-, TNF- and IL-17) and
anti-inflammatory cytokine concentrations (IL-4 and IL-10), indicating immunomodulation
induced by YM treatment. These effects on T cells were not observed immediately after STZ
injections as mice sacrificed at the 12-day time point did not demonstrate similar reductions of
proliferation or cytokine concentrations.
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Table 2
Statistically significant differences of in vivo data from YM treated mice compared to control
mice
Model

Timepoint

STZ-B6

Endpoint

YM Dose
(w/v)
4%

STZ-B6

Endpoint

2%

NOD
NOD

Endpoint
Endpoint

4%
2%

T1D Incidence

Glycemia

Body Weight

**Decreased
(80% diabetesfree)
*Decreased
(73% diabetesfree)
-

*Decreased
(maintained
normoglycemia)
*Decreased

**Increased

*Decreased
-

*Decreased
Trend
decrease

-

Note. Significance indicated by * p<0.05 or **p<.001 compared with controls (MANOVA-body
weights and blood glucose; survival testing-incidence). No significant difference is indicated by
“-”.
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Table 3
Statistically significant differences of ex vivo data from YM treated mice compared to control
mice
Model

Timepoint

YM
Dose
(w/v)
4%

Cell Counts
& Viability

Proliferation

Immunophenotypes

Cytokine
Profiles

STZB6

Endpoint

-

**Decreased

*Decreased: Treg

Early:
Day 12
Endpoint

4%

-

-

2%

**Decreased:
cell counts

*Decreased

*Decreased: Treg
*Increased: Tc
*Decreased: B cell
*Increased: Tc, T
cell

*Decreased: IL4, IL-6, IFN-,
TNF-, IL-17,
IL-10
-

STZB6
STZB6

NOD

Endpoint

4%

-

-

-

NOD
NOD

Endpoint
Early: 17
weeks

2%
4%

-

*Increased

*Decreased: T cell,
Treg

NOD

Early: 17
weeks
Early: 12
weeks

2%

-

-

4%

-

-

*Decreased: Tc,
Treg
*Decreased: T cell,
Th, Tc
**Increased: B cell

Early: 12
weeks

2%

-

*Decreased

NOD

NOD

*Decreased: Th
(Trend decrease: T
cells)
(Trend increase: B
cells)

*Decreased: IL4 (Trend
decrease: IFN-,
IL-6, TNF-,
IL-17)
*Decreased: IL4, IL-17a, IL-10
(Trend
decrease: IFN)
N/A
*Increased:
TNF-
(Trend increase:
IL-6, IL-10)
N/A
*Decreased: IL6, IFN-
(Trend
decrease: TNF, IL-17a, IL10)
N/A

Note. Significance indicated by * p<0.05 or **p<.001 compared with controls (student’s T-test).
No significant difference is shown by “-”. Decreased cell counts of 2% YM-treated STZ-B6 mice
attributed to human error.

76
Still, we cannot exclude that the anti-diabetic action of YM seen in this model may be at
least partially attributed to its polyphenols’ antioxidative action that could lessen the initial STZ
toxicity on -cells and thereby reducing induction of insulitis. STZ’s diabetogenic action is
attributed to its induction of DNA demethylation in the -cells, increased NADPH levels, and
increased reactive oxygen species (ROS) (Goyal et al., 2016). YM potentially attenuates STZ’s
action by lowering ROS (Baeza et al., 2016, Gao et al., 2013, Wang et al., 2019) and enacting
enzymes with antioxidant action (Fernandes et al., 2012, Gao et al., 2013, Lima et al., 2018).
Indeed, much research has shown anti-toxicant power of dietary polyphenols (Lagoa et al.,
2017). However, in other studies using STZ induction of diabetes, YM was administered after
confirmation of the diabetic state, so any positive benefits of YM treatment were not due to
direct action on the toxicant (Lima et al., 2018, Rocha et al., 2018).
STZ-B6 mice treated with 2% YM responded similarly to 4% YM-treated mice. They had
reduced glycemic levels and incidence compared to controls. At the 35-day endpoint, YM-treated
mice remained 73% diabetes-free whereas the control mice were 36% diabetes-free. Although
2% YM-treated mice did not gain more weight than the control mice, their weights did not differ
from the controls. Whereas immunophenotyping of T cell subpopulations showed differences
between 2% and 4% YM treatment groups, all pro-inflammatory cytokines trended low in the
2%YM treatment group, similar to the 4% YM-treated mice. However, only IL-4 was
significantly lower.
The maintenance of normoglycemia in our experiments aligns with several previously
published studies, such as those in high-dose STZ-induced diabetic mice (Lima et al., 2018),
high-dose STZ-induced diabetic rats (Rocha et al., 2018), high-fat diet (HFD)-induced obese
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mice (Pang et al., 2008; Arçari et al., 2011; Arçari et al. 2013; Kang et al., 2012; Pereira et al.,
2012), and Tsumara Suzuki obese diabetic (TSOD) mice (Hussein et al., 2011) that discovered
anti-hyperglycemic action of YM. When comparing gross and commercial mate, Silva et al.
(2011) found that gross mate caused increased blood glucose levels in male Wistar rats. This
finding, however, does not contradict the other studies. The commercially produced mate
completes four stages of preparation (singeing (blanching), drying, milling, and aging), which
reduces sucrose content compared to the gross sample, and therefore does not increase blood
glucose levels when ingested (Silva et al., 2011).
The immunosuppression in our study corresponds to the findings of studies using animal
models simulating other diseases. Luz et al. (2016) found that mice induced with carrageenan to
have pleurisy produced lower Th1/Th17 inflammatory cytokines (IL-6, IL-17A, IFN-, and TNF) and higher regulatory IL-10 when treated with YM compared to the control. Cittadini et al.
(2019) found that mice with adenocarcinoma of the lung were spared the typical inflammationinduced demyelination in the brain when treated with YM due to a reduction in the main
inflammatory cytokine, IL-6, in the brain tissues of the mice treated with YM. Carmo et al.
(2012) found that the inflammation induced by a high-fat diet in Wistar rats lessened when rats
were treated with YM. Specifically, the bone marrow cells of YM-treated rats produced less IL1a, IL-6, and TNF- compared to the control (Carmo et al., 2012).
Similarly, Arçari et al. (2011) found that the up-regulation of inflammatory genes (TNF, IL-6, and iNOS) returned to baseline with YM treatment. They concluded this return was due
to a decrease in TNF- production which halted the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-B) signaling pathway to initiate transcription of inflammatory proteins
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(Arçari et al., 2011). The immunosuppressive action of YM in the STZ-B6 model may be at least
partially explained by this interruption of the NF-B pathway by the polyphenols in YM. TNF-
causes signal transduction that leads to the translocation of NF-B into the nucleus, which then
promotes the production of pro-inflammatory cytokines (Arçari et al., 2011). If YM reduces
TNF- during the initial inflammatory event, then fewer inflammatory molecules will be coded
(e.g., IL-6 and iNOS). Our study, however, shows suppression of both pro- and antiinflammatory cytokines that is not studied in literature.
In NOD mice, 4% YM treatment caused a decrease in hyperglycemia, but it did not affect
the incidence of T1D. Unlike the STZ-B6 model, NOD mice treated with 4% YM significantly
lost weight starting around 19 weeks of age. This could be due to the length of administration of
YM for around 14 weeks as the only beverage source in NOD mice compared to 6 weeks in
STZ-B6 mice. Along with a high polyphenol content, YM also contains high levels of caffeine,
which could be deleterious to the health of these mice over a long period. The adverse effects of
YM seen in this study occurred beyond the timelines for other animal studies administering YM
treatment. The longest YM treatment via gavage was 12 weeks of 850 mg YM/kg in mice (Lima
et al., 2018), and the longest ad libitum treatment was 30 days using 7% YM in rats (Rocha et al.,
2018).
Interestingly, the level of immunosuppression found at the endpoint in the STZ-B6 mice
treated with 4% YM did not occur in the NOD model at 24 weeks of age treated with 4% YM.
Whereas immunophenotypes and T cell proliferation did not differ between treatment and control
groups in 4% YM-treated NOD mice, the concentrations of anti-inflammatory cytokines, IL-4
and IL-10, were reduced, as well as IL-17. However, at the early time point of 12 weeks of age,
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a decrease in T cells, Th, Tc populations was evident in mice treated with 4% YM compared to
the control mice, indicating YM’s effects on T cells in the pre-diabetic period. This trend
continued at 17 weeks of age, but only T cells and Treg cells were significantly lower in the YM
treatment group compared to the controls. Concurrently, T cell proliferation indices were similar
for 4% YM and control groups at the 12-weeks of age time point, but T cell proliferation indices
for 4% YM-treated mice trended higher than the control at 17 and 24 weeks of age. This change
indicates YM’s ability to reduce T cell function was limited and only evident at the earliest time
point. Cytokine data corroborates YM’s limited immunomodulatory potential in this animal
model. At 12 weeks, reduction in IL-6, IFN-, TNF-, IL-17A, and IL-10 was evident in treated
mice compared with control with statistically significant lower IL-6 and IFN-. In contrast, at 17
weeks of age, all cytokines tested were elevated, with statistically significant higher TNF-, in
YM treated mice than the controls.
NOD mice treated with 2% YM up to 24 weeks of age displayed a similar trend of
decreasing body weight starting around 18 weeks of age as the mice treated with 4% YM.
However, a trend of decreased incidence and a reduction of hyperglycemia was not observed in
mice treated with 2% YM, pointing to a difference between the low-dose YM exposure of STZB6 mice versus the NOD mouse model. 2% YM-treated NOD mice did not differ significantly
from the controls in all immunological parameters tested at the end of the experimental period.
At the early time point of 12 weeks of age, however, mice treated with 2% YM had significantly
lower Th cell populations and significantly lower T cell proliferation compared to the controls.
These data correlate with 4% YM-treated NOD mice at 12 weeks of age. At the 17 weeks of age
timepoint, the reduced proliferation was no longer seen in the YM treatment group. Instead,
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YM-treated mice had significantly lower Tc and Treg cell populations than the controls, but the
other parameters did not vary. As all in vivo data and most ex vivo data from NOD mice treated
with 2% YM did not significantly vary from the controls, cytokines were not tested.
While the NOD mice in this study were treated with YM longer than other models in
current literature, studies have shown weight loss potential with YM administration at shorter
time points. Pang et al. (2008) demonstrated that rats given an HFD supplemented with YM
extract for 60 days exhibit suppressed appetite and decreased body weight gain, visceral fat-pad
weights, adipocyte size, lipid concentrations, blood glucose, insulin, and leptin levels when
compared to rats given HFD. Pang et al. (2008) hypothesized that the weight loss was primarily
due to increased thermogenesis by up-regulating uncoupling proteins in adipose tissue, along
with increased fatty acid oxidation and lipolysis. They attributed these changes mainly to the
methylxanthines in YM (e.g., caffeine), and they attributed the hypocholesterolemic effect to the
saponins (e.g., rutin) in YM, which inhibit cholesterol metabolism and pancreatic lipase, a key
enzyme for fat digestion in the intestine (Pang et al., 2008). Arçari et al. (2009) also found that
mice given HFD for 8 weeks decreased body weight after receiving 1g YM/kg body weight daily
via gavage for 8 weeks. Food intake did not drop, but cholesterol, triglycerides, LDL cholesterol,
TNF-, IL-6, macrophage chemoattractants, and serum glucose levels did (Arçari et al., 2009).
Arçari et al. hypothesized that these changes were due to a synergistic action of the compounds
in YM: chlorogenic acid modulates glucose-6-phosphatase and decreases oxidation of LDL and
cholesterol to improve glucose tolerance; saponins interfere with cholesterol metabolism; and
methylxanthines have a contributing effect (Arçari et al., 2009). De Resende et al. (2015)
similarly concluded that the compounds in YM work synergistically through different
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mechanisms to improve lipid metabolism when they found that YM caused a reduction in LDL
plasma and intra-abdominal fat weight gain in rats fed an HFD and treated with YM for 30 days.
In a study on humans, Alkhatib (2014) found that participants who ingested 1000 mg capsule of
YM extract 60 minutes before exercising showed higher fatty acid oxidation without affecting
maximal exercise performance. This suggests that YM promotes the metabolism of fat and
possibly a glycogen sparing capacity of muscle cells (Alkhatib, 2014). Due to the weight loss
mechanisms of YM, different diet pills have been manufactured with YM extract, such as
Zotrim, Meltdown, and FitMiss Burn, which have all had varying success (Riachi & Maria,
2017).
The hypoglycemic action seen in both the NOD and STZ-B6 mice treated with 4% YM
may be attributed to YM enhancing insulin action or insulin production. In their study on the
effects of YM on glucose homeostasis, Pereira et al. (2011) hypothesized that YM contained an
insulin-secretagogue most likely from the high levels of catechin and chlorogenic acid found in
their fractions of YM used on hyperglycemic rats. In a review of current research of YM, Riachi
& Maria (2017) hypothesized that the polyphenols contained in YM might enhance the secretion
of incretins in the small intestine, which then stimulate the pancreas to produce more insulin.
This could explain why NOD and STZ-B6 mice treated with 4% YM had decreased
hyperglycemia; the remaining healthy -cells in the YM treatment group may have been pushed
to produce more insulin than the control group, thereby maintaining lower blood glucose levels
until destruction of -cell mass was complete.
To extend the investigation of YM, we employed an in-vitro approach using mouse
splenocytes to determine the direct action of this compound on T cells. From the ex vivo data of
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the STZ-B6 mice, we hypothesized that cells directly treated with YM would have decreased T
cell proliferation and decreased pro- and anti-inflammatory cytokine secretion, but this was only
partially correct. YM lowered T cell proliferation dose-dependently with significant suppression
starting at 125 µg/mL YM. Additionally, we found that 1,000 µg/mL YM decreased the
production of all cytokines tested. Such a prominent suppression of all studied cytokines in
conjunction with suppressed proliferation suggests that the highest YM concentration induced
cell death. However, the viability of cultured T cells exposed to the 1000 µg/mL YM was not
directly evaluated. Intriguingly, the next highest concentration of YM studied, 500 µg/mL, did
not elicit a similar reduction in other cytokines except in IFN- secretion. When cytokines were
analyzed, we found that YM did not elicit the general immunosuppression we hypothesized. YMinduced dose-dependent suppression was observed only for IFN-. In contrast, a dose-dependent
increase in IL-2 secretion occurred, while other cytokines did not seem to be affected by in vitro
addition of YM to the T cell cultures.
These T cell proliferation results are similar to other studies. The in vitro study of YM’s
effects on human peripheral blood T cells by Muñoz-Culla et al. (2016) found that YM
incrementally decreased activation of T cells starting at 25 µg/ml, while the concentration of 100
µg/ml and higher induced cell death. We did observe suppression of mouse T cell proliferation
starting at a concentration of approximately 8 µg/ml YM and reaching statistical significance
with the addition of 125 µg/ml YM. Our data do not support cell death induction at a dose near
100 µg/ml since T cells’ cytokine secretion was well maintained at that concentration.
Furthermore, another study described a significant reduction in colon cancer cell line
proliferation with a concentration of aqueous YM extract above 350 µg/ml of (Garcia-Lazaro,
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2020). However, other studies, using similar or different types of YM extractions, described
YM’s in vitro efficacy at lower concentrations. Wnuk et al. (2009) prepared YM as an infusion,
like we did, and found that YM increased apoptotic and necrotic cell death of human
lymphocytes in a dose-dependent manner in vitro starting at 10 µg/ml. Similarly, AmigoBenavent et al. (2017) found that several cancer cell lines treated with YM in vitro over 24 hours
decreased cell proliferation dose-dependently starting at 10 µg/ml YM from organic solvent
extract. YM at and above 10 µg/ml also reduced viability of all tested cancer cell lines, but at
concentrations below 10 µg/ml, YM had a cytoprotective effect and a dose-dependent decrease
in reactive oxygen species production (Amigo-Benavent et al., 2017). Brito et al. (2019) found
that YM from dissolved powder at concentrations of 50 µg/ml or higher increased cytotoxicity
and increased TNF- and IL-10 production in bone marrow-derived mesenchymal stromal cells,
whereas TNF- and IL-10 production was decreased at low 10 µg/mL YM concentration.
Other studies demonstrated how cells treated with YM resisted induced stress. Baeza et
al. (2016) showed that YM phenolic extract and dihydrocaffeic acid (DHCA) at concentrations of
1, 10, and 50 g/mL decreased reactive oxygen species generation, prevented macromolecular
damage, and restored glutathione that was reduced when tert-butylhydroperoxide (t-BOOH) was
added to HepG2 cells. YM and DHCA at the above concentrations showed no cytotoxic effect
when directly applied to the cells (Baeza et al., 2016). Dihydrocaffeic acid was tested along with
a YM fraction because this compound is believed to be one of the most prominent circulating
products of YM’s chlorogenic acids after metabolism in humans (Gómez-Juaristi et al., 2018). In
an earlier paper, Baeza et al. (2014) attributed the decrease in reactive oxygen species to the
antioxidant action of the chlorogenic acids in YM. Wang et al. (2019) built upon these findings
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and determined that endothelial EA.hy926 cells pre-treated with YM phenolic extracts as well as
its individual phenols and microbial metabolites (5-caffeoylquinic-acid (5-CQA), DHCA, and
dihyrdroferulic acids (DHFA)) at concentrations of 1, 10, 20 and 50 g/mL withstood stress
caused by the addition of TNF-. In particular, pre-treatment lowered ROS production, regained
reduced glutathione, and enhanced eNOS concentration, all of which show antioxidant
protection; however, YM phenol extract at or above 50 g/mL increased ROS production (Wang
et al., 2019).
For our future studies, the experimental design for the NOD model should be altered to
verify any ill effects of YM and allow improved comparison to the STZ-B6 model. Our pilot
experiment of NOD mice treated with 4% YM starting at 7-9 weeks of age also showed a trend
of delayed onset of T1D while showing a trend of lower body weights. We hypothesized that YM
treatment beginning at an earlier time point would ameliorate T1D progression, but T1D onset
was not delayed. Instead, earlier YM treatment magnified body weight reduction beginning
around 19 weeks of age. Because our data from 4% YM-treated NOD mice at the early 12
weeks of age time point showed immunomodulation of T cells, a future experiment could begin
YM treatment at 5 weeks of age but then stop YM administration around 12 weeks of age. Then
water could be offered along with YM for the remainder of the study to prevent overwhelming
the mice with long-term treatment with the extract. This period of YM administration would be
similar to that of our STZ-B6 model, which showed decreased incidence of T1D. However, it is
important to note that the NOD mouse has other immunological deficiencies that could interfere
with understanding YM’s mechanism during the development of T1D alone.
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In summary, the results showed YM treatment significantly decreased glycemia and T1D
incidence for both 4% and 2% concentrations in the STZ-B6 model over 6 weeks while
increasing or maintaining body weight with 4% and 2% concentrations, respectively. YM
treatment at 4% concentration also significantly decreased glycemia in NOD mice over 21 weeks
without affecting T1D onset, but it induced significant body weight loss starting around 19
weeks of age. With the administration of 2% YM, NOD mice showed no differences in T1D
onset, glycemia, or body weight; however, a similar trend of weight loss occurred around 19
weeks of age.
Further ex vivo data showed YM treatment significantly lowered T cell proliferation in
STZ-B6 mice administered 2% and 4% YM concentrations over 6 weeks. 4% YM administration
decreased Treg populations in STZ-B6 mice at the early timepoint and endpoint while increasing
Tc at the early time point. 2% YM administration decreased B cell populations while increasing
T cell and Tc populations in STZ-B6 mice at the endpoint. 4% and 2% YM treatment over 6
weeks also suppressed cytokine production: T cells from mice treated with 4% YM produced
lower pro-inflammatory ( IL-6, IFN-, TNF-, and IL-17) and anti-inflammatory (IL-4 and IL10) cytokines; and T cells from mice treated with 2% YM produced significantly decreasing antiinflammatory IL-4 and a trend of lowering pro-inflammatory cytokines.
4% YM treatment in NOD mice showed a transient beneficial effect at the 12 weeks of
age timepoint as production of inflammatory cytokines, IL-6 and IFN-, decreased. T cell, Th,
and Tc populations also were lowered while B cell populations increased. However, with time,
4% YM showed no anti-inflammatory action in NOD mice as T cell proliferation, and proinflammatory TNF- production increased at the 17 weeks of age timepoint. Furthermore, anti-
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inflammatory cytokine production of IL-4 and IL-10 decreased while pro-inflammatory IL-17a
increased at the endpoint. 2% YM treatment in NOD mice showed no effect on T1D incidence,
glycemia, cell viability, T cell proliferation, or immunophenotypes at the endpoint, but it caused
transient, inconsistent changes in T cell subpopulations at the earlier time points.
In vitro data on ConA-stimulated splenocytes directly exposed to 0-1000 g/mL YM
showed a dose-dependent reduction in T cell proliferation starting at a concentration of
125 mg/mL YM. Cytokine production by these splenocytes was significantly suppressed with
1000 mg/mL YM but not by 500 g/mL YM. A trend of incrementally decreased IFN- and a
trend of incrementally increased IL-2 occurred with increasing concentrations of YM, but no
significant patterns in IL-4, IL-6, TNF-, IL-17a, or IL-10 production was evident.
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Chapter 6: Conclusion
In conclusion, our study for the first time shows that YM treatment prevented T1D
development in the STZ-B6 mouse model. The inhibition of T1D onset was due in part to
immunomodulatory action on T cells as YM treatment reduced their proliferative potential and
suppressed production of both pro-inflammatory and anti-inflammatory cytokines. Interestingly,
whereas YM reduced hyperglycemia in both STZ-B6 and NOD mice, it did not affect diabetes
development in the NOD model regardless of the transient reduction of T cells and suppression
of pro-inflammatory cytokine production at the early point in disease progression.
The results presented elucidate an immunomodulatory effect of YM corroborated by
current literature in both in vivo and in vitro models. YM’s effect on T1D development should be
expanded, given the potential benefits of delayed onset of the disease, reduced glycemia, and
immunosuppression substantiated in this study. Nevertheless, further studies are needed to
address the safety of YM consumption over a prolonged timeline as YM treatment induced
significant weight loss around 14 weeks of YM administration with only transient benefit in the
NOD model. Finally, a greater understanding of the interaction of compounds found in YM will
assist in illuminating the mechanisms of the outcomes observed.
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